STOCK TITAN

Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ: SBFM)

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Sunshine Biopharma Inc. (NASDAQ:SBFM) has successfully completed a $19.5 million private placement, with Aegis Capital Corp. serving as the exclusive placement agent. This financing will support the advancement of its lead compound, SBFM-PL4, targeting COVID-19, and Adva-27a, an anticancer drug effective against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned in collaboration with McGill University. The company holds all patents related to Adva-27a, highlighting its strong position in developing innovative therapeutics.

Positive
  • Successful completion of $19.5 million private placement enhances liquidity.
  • Advancement of SBFM-PL4 targeting COVID-19 indicates progress in treatment development.
  • Adva-27a shows effectiveness against multidrug-resistant cancer cells.
  • Clinical trials for pancreatic cancer planned at reputable McGill University.
Negative
  • None.

NEW YORK, NY / ACCESSWIRE / April 28, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $19.5 Million Private Placement Priced At-the-Market for Sunshine Biopharma Inc. (NASDAQ:SBFM)

About Sunshine Biopharma, Inc.

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. The Company is currently advancing the development of SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

For more information, visit www.sunshinebiopharma.com

Sunshine Biopharma, Lonza manufacture anti-cancer drug

About Aegis Capital Corporation

Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.

For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.

Shape, logoDescription automatically generated

www.aegiscapcorp.com

Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

SOURCE: Aegis Capital Corp.



View source version on accesswire.com:
https://www.accesswire.com/699266/Aegis-Capital-Corp-acted-as-Exclusive-Placement-Agent-on-a-195-Million-Private-Placement-Priced-At-the-Market-for-Sunshine-Biopharma-Inc-NASDAQ-SBFM

FAQ

What was the amount of the private placement for Sunshine Biopharma (SBFM)?

The private placement for Sunshine Biopharma amounted to $19.5 million.

What are the main projects Sunshine Biopharma is working on?

Sunshine Biopharma is developing SBFM-PL4 for COVID-19 and Adva-27a for treating various cancers.

Where will the clinical trials for pancreatic cancer be conducted?

The clinical trials for pancreatic cancer will be conducted at McGill University's Jewish General Hospital.

Who acted as the placement agent for Sunshine Biopharma's private placement?

Aegis Capital Corp. acted as the exclusive placement agent for the private placement.

What is the focus of Sunshine Biopharma's lead compound SBFM-PL4?

SBFM-PL4 focuses on inhibiting the replication of the SARS-CoV-2 virus, responsible for COVID-19.

Sunshine Biopharma Inc.

NASDAQ:SBFM

SBFM Rankings

SBFM Latest News

SBFM Stock Data

6.48M
1.99M
0.23%
1.84%
11.7%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
FORT LAUDERDALE